BlackRock Discloses 5.0% Stake in Immuneering Corp
Ticker: IMRX · Form: SC 13G · Filed: Jan 26, 2024 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | SC 13G |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, stake-disclosure, pharmaceuticals
TL;DR
**BlackRock just revealed a 5% stake in Immuneering, a bullish sign!**
AI Summary
BlackRock Inc., a major investment firm, reported on January 26, 2024, that as of December 31, 2023, it beneficially owns 2,058,406 shares of Immuneering Corp's Class A Common Stock. This represents a 5.0% ownership stake in the pharmaceutical company. This matters to investors because BlackRock's significant stake indicates their confidence in Immuneering's future, potentially signaling a positive outlook for the stock.
Why It Matters
BlackRock's substantial investment in Immuneering Corp signals institutional confidence, which can positively influence other investors and potentially stabilize or boost the stock price.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investor has taken a significant stake, which generally adds stability and confidence to a stock.
Analyst Insight
A smart investor would view BlackRock's 5.0% stake as a vote of confidence, potentially signaling a good long-term hold for Immuneering Corp, and might consider further research into the company's fundamentals.
Key Numbers
- 2,058,406 — Shares Owned (Number of Immuneering Corp Class A Common Stock shares beneficially owned by BlackRock Inc.)
- 5.0% — Ownership Stake (Percentage of Immuneering Corp Class A Common Stock owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — reporting person, investment firm
- Immuneering Corp (company) — subject company, pharmaceutical preparations
- 2,058,406 (dollar_amount) — shares beneficially owned by BlackRock
- 5.0% (dollar_amount) — percentage of Class A Common Stock owned by BlackRock
- December 31, 2023 (person) — date of event requiring the filing
- January 26, 2024 (person) — filing date
Forward-Looking Statements
- Immuneering Corp's stock price may experience increased stability due to BlackRock's significant institutional ownership. (Immuneering Corp) — medium confidence, target: next 6-12 months
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock Inc., a major investment management company, as stated in the 'FILED BY' section of the filing.
What is the subject company of this filing?
The subject company is Immuneering Corp, a pharmaceutical preparations company, as identified in the 'SUBJECT COMPANY' section.
How many shares of Immuneering Corp's Class A Common Stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 2,058,406 shares of Immuneering Corp's Class A Common Stock, as indicated in the filing's cover page.
What percentage of Immuneering Corp's Class A Common Stock does BlackRock Inc. own?
BlackRock Inc. owns 5.0% of Immuneering Corp's Class A Common Stock, as detailed on the cover page of the SC 13G filing.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified on the first page of the Schedule 13G.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 26, 2024 by December 31, 2023 regarding Immuneering Corp (IMRX).